{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:23:35Z","timestamp":1780752215737,"version":"3.54.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750.2022-16-3"],"award-info":[{"award-number":["320.6750.2022-16-3"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Association for Cancer Control and Prevention","award":["CAPTRALung2021008"],"award-info":[{"award-number":["CAPTRALung2021008"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Leptomeningeal metastases (LMs) are serious complications of non-small cell lung cancer (NSCLC). This study aimed to investigate the safety and efficacy of intrathecal immune checkpoint inhibitors (ICIs) in treating NSCLC-LM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted this prospective phase 1 study (ChiCTR2200062245) using a traditional \u201c3+3\u201d design with intrathecal sintilimab (dose escalation 10, 20, 30, and 40 mg) for NSCLC-LM patients who had progressed from targeted therapy and intrathecal pemetrexed. The primary study endpoints were safety and recommended dose, and the secondary endpoints included clinical response rate, progression-free survival (PFS), intracranial progression-free survival (iPFS), and overall survival (OS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No dose-limiting toxicity was found at 10, 20, 30, and 40 mg for intrathecal sintilimab. Therefore, sintilimab 40 mg was recommended for intrathecal injection. A total of 19 patients were enrolled in this study. The median age at diagnosis of LM was 53 years. The overall incidence of adverse events (AEs) was 68.4%, and rash (n\u2005=\u20054, 21.1%) was the most common AEs, which returned to normal after symptomatic treatment. As 1 patient was lost to follow-up and 18 patients could be evaluated for efficacy, the clinical response rate was 38.9% (7\/18). Median PFS was 3.5 months (95% CI: 2.7\u20134.2 months), median iPFS was 3.5 months (95% CI: 1.3\u20135.6 months), and median OS was 11.5 months (95% CI: 0.0\u201325.4 months).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Intrathecal ICIs for NSCLC-LM patients are safe, and the recommended dose of sintilimab is 40 mg. Intrathecal sintilimab for NSCLC-LM failed from multi-line therapies, showed potential effectiveness in some patients, and is worthy of further study.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noaf025","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:02:47Z","timestamp":1738580567000},"page":"1559-1566","source":"Crossref","is-referenced-by-count":7,"title":["Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study)"],"prefix":"10.1093","volume":"27","author":[{"given":"Chengjuan","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanju","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixi","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Man","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2798-5068","authenticated-orcid":false,"given":"Tao","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Affiliated Hospital of Harbin Medical University , Harbin ,","place":["People\u2019s Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"1","key":"2025073013013955100_CIT0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non-small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clinical Cancer Res"},{"issue":"3","key":"2025073013013955100_CIT0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-021-03924-2","article-title":"Leptomeningeal metastases: the future is now","volume":"156","author":"Lukas","year":"2022","journal-title":"J Neurooncol."},{"issue":"23","key":"2025073013013955100_CIT0003","doi-asserted-by":"crossref","first-page":"JCO2400708","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II Efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025073013013955100_CIT0004","first-page":"538","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study","volume":"38","author":"James C","year":"2019","journal-title":"J Clin Oncol."},{"key":"2025073013013955100_CIT0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.09.013","article-title":"Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment","volume":"174","author":"Wang","year":"2022","journal-title":"Lung Cancer."},{"issue":"6","key":"2025073013013955100_CIT0006","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1007\/s13311-022-01261-4","article-title":"Leptomeningeal metastases: New opportunities in the modern era","volume":"19","author":"Wilcox","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"5","key":"2025073013013955100_CIT0007","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood-brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat Rev Drug Discov."},{"issue":"10","key":"2025073013013955100_CIT0008","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41571-023-00808-4","article-title":"Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer","volume":"20","author":"Kelsey","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"issue":"0","key":"2025073013013955100_CIT0009","first-page":"114338","article-title":"Intrathecal delivery and its applications in leptomeningeal disease","volume":"186","author":"Minsoo","year":"2022","journal-title":"Adv Drug Deliv Rev."},{"issue":"6","key":"2025073013013955100_CIT0010","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2020.10.001","article-title":"SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids","volume":"27","author":"Laura","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"8","key":"2025073013013955100_CIT0011","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","article-title":"Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC-a prospective, open-label, single-arm phase 1\/2 clinical trial (Unique Identifier: ChiCTR1800016615)","volume":"16","author":"Fan","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2025073013013955100_CIT0012","doi-asserted-by":"crossref","first-page":"102384","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: An expanded, single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"issue":"10","key":"2025073013013955100_CIT0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Michael","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"3","key":"2025073013013955100_CIT0014","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Itziar","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"issue":"8","key":"2025073013013955100_CIT0015","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell."},{"issue":"1","key":"2025073013013955100_CIT0016","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","article-title":"Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases","volume":"12","author":"Prakadan","year":"2021","journal-title":"Nat Commun."},{"issue":"2","key":"2025073013013955100_CIT0017","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2025073013013955100_CIT0018","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol."},{"issue":"11","key":"2025073013013955100_CIT0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/OP.20.00146","article-title":"Treatment of metastatic melanoma with leptomeningeal disease using intrathecal immunotherapy","volume":"16","author":"Huppert","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025073013013955100_CIT0020","doi-asserted-by":"crossref","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann Oncol."},{"issue":"4","key":"2025073013013955100_CIT0021","first-page":"484","article-title":"Leptomeningeal metastases: A RANO proposal for response criteria","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"issue":"12","key":"2025073013013955100_CIT0022","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cac2.12385","article-title":"Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: An open-label, randomized controlled phase 3 trial (ORIENT-3)","volume":"42","author":"Shi","year":"2022","journal-title":"Cancer Commun (Lond)"},{"key":"2025073013013955100_CIT0023","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2021.03.037","article-title":"Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments","volume":"150","author":"Zheng","year":"2021","journal-title":"Eur J Cancer"},{"issue":"0","key":"2025073013013955100_CIT0024","first-page":"182","article-title":"Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors","volume":"116","author":"Lizza E","year":"2019","journal-title":"Eur J Cancer."},{"issue":"4","key":"2025073013013955100_CIT0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","article-title":"Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: Phase 1 trial interim results","volume":"29","author":"Glitza Oliva","year":"2023","journal-title":"Nat Med."},{"key":"2025073013013955100_CIT0026","doi-asserted-by":"crossref","first-page":"xii33","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2025073013013955100_CIT0027","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: Lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaf025\/61741674\/noaf025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/6\/1559\/61741674\/noaf025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/27\/6\/1559\/61741674\/noaf025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:01:46Z","timestamp":1753894906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/27\/6\/1559\/7997391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":27,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,7,30]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaf025","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,2,3]]}}}